In spite of significant improvement after multi-modality treatment, prognosis most patients with glioblastoma remains poor. Standard clinical prognostic factors (age, gender, extent surgery and performance status) do not clearly predict long-term survival. The aim this case-control study was to evaluate immuno-histochemical genetic characteristics the tumour as additional in glioblastoma.Long-term survivor group were 40 survival longer than 30 months. Control shorter matched according...

After a favorable experience with gemcitabine at low dose in prolonged infusion combination cisplatin for advanced non-small-cell lung cancer, here, we present the results from phase II trial patients malignant pleural mesothelioma. Eligible had biopsy-proven mesothelioma, were chemo-naive, Eastern Cooperative Oncology Group performance status 0-2, normal hematopoietic liver and renal function, gave informed consent. Treatment consisted of 250 mg/m 6-h on days 1 8 75 day 2 3-week cycle four...

The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to development treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[18F] fluoroethyl-)-L-tyrosine (18F-FET) has been shown be useful tool for detecting TRC and TP. We assessed diagnostic performance different 18F-FET PET segmentation approaches imaging biomarkers differentiation between late TP patients. Isocitrate...

After monotherapy with gemcitabine in low dose long infusion, promising results a variety of advanced chemoresistant tumors have been reported. In previous phase I trial on heavily pre-treated patients, maximum tolerated (MTD) 6 h infusion was 250 mg/m. The objective our I-II to test the combination 6-h and cisplatin treatment non-small cell lung cancer (NSCLC). Eligible patients were chemonaive, had locally or metastatic NSCLC, Eastern Oncology Cooperative Group performance status 0-2...

We present experience from a phase II randomized clinical trial, comparing standard gemcitabine as monotherapy with low-dose in long infusion doublet cisplatin at reduced dose for patients non-small cell lung cancer (NSCLC) and who are unfit platin-based chemotherapy. Eligible had microscopically confirmed NSCLC stage IIIB (wet) or IV, were chemo-naive, poor performance status presented significant comorbidity. Standard treatment gemcitabine, 1250 mg/m 20-30 min on days 1 8 (arm A) was...

Abstract Background Glioblastoma has in last 20 years seen the steady increase of incidence, which is most prominent group older patients. These than 70 have significantly poorer prognosis other patients and are considered a distinct glioblastoma Modified prognostic factors being used these this information lately supplemented with genetic epigenetic on tumour. The therapy now often tailored accordingly. aim our study was to analyse current treatment over age determine impact clinical...

Glioblastoma is the most common primary brain tumour. It has a poor prognosis despite some advances in treatment that have been achieved over last ten years. In Slovenia, 50 to 60 glioblastoma patients are diagnosed each year. order establish whether current options any influence on survival of Slovenian patients, their data period from beginning year 1997 end 2008 analysed.All treated at Institute Oncology Ljubljana were included retrospective study. Demographics, details, and time after...

Intermittent application of chemotherapy and tyrosine kinase inhibitors may avoid antagonism between the two classes drugs. This hypothesis was tested in a Phase II clinical trial.Eligible patients were nonsmokers or light smokers, chemo-naïve, with metastatic adenocarcinoma lung.4 to 6 cycles gemcitabine 1250 mg/m(2) on days 1 4, cisplatin 75 day 2, erlotnib 150 mg daily 5-15, followed by erlotinib as maintenance.24 entered trial. Four pts had grade 3 toxicity. Complete remission (CR)...

Oliogodendrogliomas are brain tumours composed of the cells resembling oligodendrocytes. They represent third most common glial tumour, comprising 2.5% all primary and 5-20% gliomas.Oligodendroglial with 1p 19q loss demonstrate a better overall prognosis due to more indolent clinical behaviour higher sensitivity treatment. Additionally, is marker utility, helping assess tumour chemotherapy harbouring potential for improving diagnosis survival oligodendroglioma patients as well future practice.

AimTo investigate the prognostic factors of survival in patients with high-grade gliomas without isocitrate dehydrogenase-1 (IDH) mutation and O 6 -methylguanine-DNA methyltransferase (MGMT) methylation.MethodsThe study enrolled Slovenian gliomas. Postoperatively, they completed a battery neuropsychological tests. Demographics clinical data were collected. The results cognitive tests converted to standardized scores dichotomized based on impairment. A univariate Cox proportional hazard...

High grade gliomas are associated with cognitive problems. The aim of the study was to investigate functioning in a cohort patients high glioma, according isocitrate dehydrogenase (IDH) and methyl guanine transferase (MGMT) status other clinical characteristics.The high-grade glioma treated Slovenia given period time were included study. Postoperatively they completed neuropsychological assessment consisting Slovenian Verbal Learning Test, Controlled Oral Word Association Trail Making Test...

Abstract INTRODUCTION: High-grade gliomas without isocitrate dehydrogenase (IDH) mutations are associated with poor survival and have been poorly studied. Our aim was to investigate the prognostic factors for in this group, focusing on frailty, age, cognition. METHODS: This study included Slovenian patients high-grade IDH1 wild-type gliomas. Frailty cognitive functioning were measured postoperatively using Clinical Scale neuropsychological test battery. Descriptive statistics used analyze...

Abstract BACKGROUND Hyper Arc is an innovative software introduced at the Institute of Oncology Ljubljana in June 2020. It enables high-precision treatment multiple brain lesions with a single isocenter and potential to address unlimited number targets. This particularly useful local metastases, which are increasingly common causes morbidity mortality patients malignant diseases. Based on latest research guidelines, stereotactic radiosurgery considered primary choice improve survival may be...

The aim of this work was to evaluate whether the excising margin clinical tumor volume and planning target correspond with calculated radiation based on systematic errors, definition margins individual brain lobes. This research a retrospective cross-sectional study. We checked errors their average size margins. were in four directions: lateral, longitudinal, vertical, rotation. largest error lateral direction cerebellar area, also statistically significant(p < 0.05). In rotational we...

Glioblastoma is the most common primary brain tumor. It peaks its incidence in seventh decade. In recent years we are observing a steady rise number of glioblastoma patients their 70s and 80s. We do not know optimal treatment for these patients. our database searched older than 70 reporting characteristics outcome. From 1999 to 2013, 799 with were treated at Institute Oncology Ljubljana. Of those 151 or more. While first five observation period, there 9% over 70, 22% afterwards. periods also...